Table 2.
Characteristics | Parameters | hiPSC-CMs | Human Adult CMs | Assessment Methods | |
---|---|---|---|---|---|
Morphology and Microstructure |
Cell Shape | Round shape | Rod shape, anisotropic | Imaging Immunostaining to assess structural features |
|
Cell size | Length | 5–10 μm (diameter) | 150 μm | ||
Width | 20 μm | ||||
Height | 5 μm | 15 μm | |||
Volume | 2000 μm3 | 40,000 μm3 | |||
Length/width ratio | — | 7:1 | |||
Nucleation and ploidy | Mononucleated, diploidy | Binucleated (25%) and polyploidy | |||
Sarcomere | 1.6 μm, disorganized | 1.8 μm (contracted)-2.2 μm (relaxed), organized | |||
Enriched isoforms | α-MHC, ssTnI, MLC2A, N2BA, SMA |
β-MHC, cTnI, MLC2V, N2B | |||
Other microstructures | Lack T-tubules and M-band; poor SR, mitochondria; circumferential IDs | Developed and abundant microstructures; polarized IDs | |||
Electrophysiology | Beating | Beating spontaneously or stimulated by a 0.08–4 mN/mm2 force | Beating only when stimulated by a 40–80 mN/mm2 force | Patch clamp and MEAs for ion channels and AP currents Video-optical recording, atomic force microscopy (AFM). and muscle thin films (MTFs) for contractile force measurements (Frank–Starling relationship) |
|
Membrane capacitance | ~20 pF | ~190 pF | |||
Conduction velocity | 10–20 cm/s | 60 cm/s | |||
Upstroke velocity | 10–50 V/s | 150–350 V/s | |||
Action potential | −60 mV (like nodal) | −90 mV | |||
Specific currents | I Kf | I K1 | |||
Calcium Handling | ECC | Slow | Fast | Calcium imaging using fluorescent calcium indicators | |
Ion channels | NCX | LTCC-β2 (20-fold higher), RyRs (1000 folds higher), calsequestrin, SERCA | |||
Metabolism | Mitochondria | Round shape with poor cristae | Oval shape with developed cristae; active fission and fusion | Mass spectrometry (MS) and nuclear magnetic resonance spectroscopy (NMR) for metabolic flux assays Oxygen consumption and extracellular acidification rate to access mitochondria respiration Imaging and fluorescent staining for mitochondrial membrane potential (MMP) |
|
Abundance (% to cell volume) | <5% | ~30% | |||
Location | Perinuclear space | Between myofibrils and under sarcolemma | |||
Metabolic substrate | Glucose (85%), fatty acid (15%) | Fatty acid (80%), glucose (20%) | |||
ATP source | Anaerobic glycolysis | FAO | |||
Gene Expression | Upregulated genes | Cell-cycle genes: CDK Automaticity genes: HCN4, KCNJ2 Fetal/natal isoform genes Glycolysis-related genes |
Cell-cycle arrest genes: CDKI Overall upregulation of structure organization and function development genes |
Imaging Flow cytometry to access cell cycle Fluorescent staining |
AFM, atomic force microscopy; AP, action potential; cTnI, cardiac muscle troponin I; ECC, excitation–contraction coupling; FAO, fatty-acid oxidation; ID, intercalated disc; LTCC-β2: L-type calcium channel β subunit; MEA, microelectrode array; MLC2A, myosin regulatory light chain 2 atrial isoform; MLC2V, myosin regulatory light chain 2 ventricular isoform; MMP, mitochondrial membrane potential; MS, mass spectrometry; MTF, muscle thin film; N2B; titin isoform type containing only N2B elements; N2BA, titin isoform type containing both N2A and N2B elements; NCX, Na+–Ca2+ exchanger; NMR, nuclear magnetic resonance spectroscopy; RyR2, ryanodine receptor 2; SERCA, sarco/endoplasmic reticulum Ca2+ ATPase; SMA, smooth muscle actin; SR, sarcoplasmic reticulum; ssTnI, slow skeletal muscle troponin I; α-MHC, myosin heavy chain α-isoform; β-MHC, myosin heavy chain β-isoform; pF, picofarad.